

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ashkenazi et al.  
Appl. No. : 09/978,193  
Filed : October 15, 2001  
For : SECRETED AND  
TRANSMEMBRANE  
POLYPEPTIDES AND  
NUCLEIC ACIDS  
ENCODING THE SAME  
Examiner : Unknown  
Group Art Unit : Unknown

I hereby certify that this correspondence and all  
marked attachments are being deposited with the  
United States Postal Service as first class mail in an  
envelope addressed to: Commissioner for Patents,  
Washington, D.C. 20231, on

February 11, 2002

(Date)

*Ginger Dreger*  
Ginger R. Dreger, Reg. No. 33,055

## TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Dear Sir:


Enclosed for filing in the above-identified application is the following:

- (X) Amendment
- (X) Sequence Submission Statement in 429 pages;
- (X) Substitute Sequence Listing in computer readable form;
- (X) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410; and

- (X) A return prepaid postcard.

*Ginger Dreger*  
Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/978,193	10/15/2001	Avi J. Ashkenazi	P2630P1C6

CONFIRMATION NO. 4687

## FORMALITIES LETTER



\*OC00000007180950\*

Ginger R. Dreger, Esq.  
Knobbe Martens Olson & Bear  
Suite 1150  
201 California Street  
San Francisco, CA 94111

Date Mailed: 12/11/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice MUST be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202  
PART 2 - COPY TO BE RETURNED WITH RESPONSE

GNE.P2630P1C6

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant : Ashkenazi et al.  
Appl. No. : 09/978,193  
Filed : October 15, 2001  
For : SECRETED AND  
TRANSMEMBRANE  
POLYPEPTIDES AND NUCLEIC  
ACIDS ENCODING THE SAME  
Examiner : Unknown

) Group Art Unit Unknown  
I hereby certify that this correspondence and all  
marked attachments are being deposited with the  
United States Postal Service as first-class mail in  
an envelope addressed to: Commissioner for  
Patents, Washington, D.C. 20231, on  
February 11, 2002  
(Date)  
Ginger R. Dreger, Reg. No. 33,055

SEQUENCE SUBMISSION STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed December 11, 2001.  
I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a) and included in the  
Substitute Sequence Listing submitted herewith, are supported in the application, and that the Substitute  
Sequence Listing does not include new matter.

I further state that the information recorded in the currently submitted substitute copy of the  
computer-readable form of the Sequence Listing is identical to the paper form of the Sequence Listing  
submitted herewith as required in 37 C.F.R. § 1.825(b).

Please charge any additional fees, including any fees for additional extension of time, or credit  
overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By:

Ginger R. Dreger  
Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record  
620 Newport Center Drive, 16<sup>th</sup> Floor  
Newport Beach, CA 92660  
(415) 954-4114

Dated: February 11, 2002